Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 2.42
- Piotroski Score 1.00
- Grade N/A
- Symbol (ATEK)
- Company Athena Technology Acquisition Corp. II
- Price $11.99
- Changes Percentage (2.3%)
- Change $0.27
- Day Low $11.99
- Day High $11.99
- Year High $13.41
Athena Technology Acquisition Corp. II does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company focuses on identifying businesses in the fintech, enterprise, deep tech, and health-tech industries. Athena Technology Acquisition Corp. II was incorporated in 2021 and is based in New York, New York.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/18/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.08
- Trailing P/E Ratio 141.5
- Forward P/E Ratio 141.5
- P/E Growth 141.5
- Net Income $1.34 M
Income Statement
Quarterly
Annual
Latest News of ATEK
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Conduktor looks to gatekeep 'bad data' out of company's apps
In 2020, Nicolas Orban, Stéphane Derosiaux, and Stéphane Maarek founded Conduktor to enhance Apache Kafka for managing real-time data streams. The platform filters and controls data flow, meeting th...
By Yahoo! Finance | 5 days ago -
Paratek's antibiotic succeeds in Phase IIb lung disease trial
Paratek Pharmaceuticals reports positive Phase IIb trial results for oral antibiotic Nuzyra in treating NTM pulmonary disease. The therapy shows improvement in symptoms with favorable trends observed....
By Yahoo! Finance | 6 days ago -
Krejcikova beats Gauff to earn last semifinal spot at WTA Finals. Swiatek eliminated despite win
Barbora Krejcikova secured the final spot in the WTA Finals semis by defeating Coco Gauff, eliminating Iga Swiatek. Krejcikova will face Zheng, while Gauff will play Sabalenka. Swiatek lost due to set...
By AP NEWS | 1 week ago
